Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium
GuardantINFORM™Â platform offers real-world evidence to identify unmet need for patients with advanced breast cancer December 06, 2021 08:05 AM Eastern Standard Time REDWOOD CITY, Calif.–(BUSINESS WIRE)–sGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present new data demonstrating the benefits of using the Guardant360® liquid biopsy…